CTC1

Across TCGA pan-cancer cohorts, CTC1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTC1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CTC1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CTC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.249	1.000	.038	12	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.691	.003	6	view →
CCRCC	OS	Tertile	II,III,IV	0.747	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CTC1–PDAC (OS)

Open the PDAC breakdown →